While the c. €1tn Pharma sector has been going essentially nowhere between failed phase III drugs and Trump-driven uncertainty, the €133bn MedTech sector has been flying over the last…
The average target price according to our valuation should be around €40 per share. We recommend to subscribe. Attractive IPO price range between €26 and…